Ricarda G. S.
- Country
- Spain
- Department
- Servicio de Hematologia
Research Overview
- Phase 1 Evaluation of GSK2857916 Combined with Standard of Care in Newly Diagnosed Multiple Myeloma Patients
- Phase 2, multicenter, open‑label study of extended‑dosing belantamab mafodotin in combination therapy for relapsed/refractory multiple myeloma
- Phase III Randomized Trial of Bortezomib, Melphalan, Prednisone, Lenalidomide, Dexamethasone, Carfilzomib, and Daratumumab in Elderly Patients with Newly Diagnosed Multiple Myeloma
Data & Insights
Has run more than one trial at 80 of 212 partner sites.
Specializations
Hematologic malignancies
Ricarda Garcia Sánchez is involved in clinical research across a broad spectrum of blood cancers, with activity in acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma, lymphoma, and myelofibrosis. Her portfolio also includes studies in chronic myeloid leukemia and other bone marrow disorders.
- Acute myeloid leukemia
- Multiple myeloma
- Myelodysplastic syndrome
- Lymphoma
- Myelofibrosis
Her work in hematology reflects interest in both relapsed and newly diagnosed disease settings, with emphasis on therapeutic innovation in hematologic oncology.
Breast and gynecologic oncology
Her clinical research includes extensive involvement in breast cancer, particularly hormone receptor-positive, HER2-negative, HER2-positive, and triple-negative breast cancer, as well as early breast cancer and metastatic disease. She is also engaged in studies of ovarian cancer, endometrial cancer, cervical cancer, and other gynecologic malignancies.
- Breast cancer
- Triple-negative breast cancer
- HER2-positive breast cancer
- Ovarian cancer
- Endometrial cancer
Her oncology portfolio spans neoadjuvant, adjuvant, and advanced/metastatic treatment contexts in women’s cancers.
Thoracic, genitourinary, and solid tumor oncology
Ricarda Garcia Sánchez is active in research on non-small cell lung cancer, small cell lung cancer, renal cell carcinoma, bladder cancer, prostate cancer, and a wide range of advanced solid tumors. Her trial activity also extends to head and neck squamous cell carcinoma, pancreatic cancer, and colorectal cancer.
- Non-small cell lung cancer
- Prostate cancer
- Bladder cancer
- Renal cell carcinoma
- Head and neck squamous cell carcinoma
Her involvement supports research in targeted therapy and immuno-oncology across multiple tumor types.
Cardiometabolic and vascular disease
Her clinical trial landscape includes atherosclerotic cardiovascular disease, heart failure, atrial fibrillation, myocardial infarction, hypertension, and dyslipidemia. She is also involved in studies addressing obesity, type 2 diabetes, and severe hypertriglyceridemia.
- Atherosclerotic cardiovascular disease
- Heart failure
- Atrial fibrillation
- Type 2 diabetes
- Obesity
Her work also covers cardiovascular prevention and therapies aimed at reducing thromboembolic and metabolic risk.
Liver, pulmonary, and inflammatory disorders
Ricarda Garcia Sánchez is engaged in clinical research on non-alcoholic steatohepatitis, primary biliary cholangitis, hepatitis B, and hepatitis C, alongside respiratory conditions such as chronic obstructive pulmonary disease, asthma, and idiopathic pulmonary fibrosis. Her portfolio also includes hidradenitis suppurativa, atopic dermatitis, and other inflammatory diseases.
- Non-alcoholic steatohepatitis
- Primary biliary cholangitis
- Chronic obstructive pulmonary disease
- Idiopathic pulmonary fibrosis
- Hidradenitis suppurativa
Her research interests include liver disease, airway inflammation, and immune-mediated conditions requiring new therapeutic options.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.